The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.
University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...
Now that colder temperatures have arrived, the Illinois Department of Public Health (IDPH) is reminding Illinoisans to ...
Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...
RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...
Newborns whose mothers have not received the RSV vaccine, should receive Nirsevimab between October and March. Public health leaders stress one of the best ways to reduce transmission of viruses is to ...
Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...